Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Solriamfetol is a central stimulant with actions similar to modafinil, although they are not structurally related. Selectively inhibits the reuptake of dopamine and norepinephrine. It is used in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Oral administration once daily.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data do not allow to predict its possible excretion in breast milk. Its low protein binding and low molecular weight would favor it, but the high volume of distribution would prevent it.
The manufacturer (Jazz 2021, FDA 2019) and expert authors (LactMed) consider its administration possible during lactation, monitoring the infant for signs of irritability, insomnia, diarrhea, appetite and adequate weight gain.
See below the information of this related product: